Group Oncorad

Based in Morocco, Group Oncorad specializes in advanced medical solutions, focusing on robotic surgical interventions and telemedicine services, enhancing healthcare access and quality for patients. Group Oncorad, founded in 1999 and headquartered in Casablanca, Morocco, provides innovative healthcare solutions primarily in robotic surgeries and telemedicine. The company has completed 2 deals, with the most recent deal occurring on May 11, 2023, during which CDG Capital Private Equity and STOA Infra and Energy acquired a 24. 40% minority stake for MAD 458 million.

The funding will support the company’s initiatives in enhancing cancer treatment and surgical care throughout Morocco. Oncorad Group specializes in advanced medical solutions, with a primary focus on robotic surgical interventions and telemedicine services. Their core product offerings include robotic-assisted surgeries, particularly in urology, exemplified by their groundbreaking achievement of performing a total prostatectomy from a distance of 12,000 km between Casablanca and Shanghai. This innovative technology is designed to enhance surgical precision, reduce postoperative pain, and facilitate quicker recovery times for patients.

Oncorad Group's services cater to a diverse clientele, including hospitals and healthcare facilities, primarily in Morocco and expanding into other regions across Africa. The company positions itself as a leader in improving access to specialized healthcare, especially for patients in remote areas, ultimately aiming to enhance the quality of life for individuals requiring advanced medical care. Oncorad Group generates revenue through its specialized surgical services and technological innovations within the healthcare sector. The company engages in direct-to-consumer transactions, providing patients with access to cutting-edge robotic surgeries and personalized medical care.

These services are typically structured around partnerships with hospitals and healthcare providers, facilitating the integration of their advanced surgical technology into existing medical frameworks. Oncorad Group's pricing structure is reflective of the value provided through its flagship robotic surgical procedures, ensuring that clients receive high-quality care tailored to their specific needs. The company's commitment to innovation and quality positions it favorably within the healthcare market, driving both patient retention and institutional partnerships as it expands its service offerings. In May 2023, the investment from CDG Capital Private Equity and STOA Infra and Energy will enable Group Oncorad to enhance its quality of care delivery across Morocco, particularly in cancer treatment and surgery.

The company is expected to focus on expanding its market presence, particularly into other regions of Africa. The funding of MAD 458 million will be crucial in supporting these growth initiatives.